Drug Profile
Azithromycin ophthalmic - Laboratoires Thea
Alternative Names: Azydrop; Azyter; AzyterA; Bazyt; T-1225Latest Information Update: 23 Dec 2021
Price :
$50
*
At a glance
- Originator Laboratoires Thea
- Developer Laboratoires Thea; Spectrum Thea Pharmaceuticals
- Class Anti-inflammatories; Antibacterials; Antivirals; Eye disorder therapies; Macrolides; Small molecules
- Mechanism of Action Protein 50S ribosomal subunit inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Infectious conjunctivitis
- Phase III Bacterial infections
- Discontinued Blepharitis
Most Recent Events
- 24 Sep 2021 Discontinued - Phase-II for Bacterial infections (Prevention) in France, Spain (Ophthalmic)
- 24 Sep 2021 Discontinued - Phase-II for Blepharitis in France (Ophthalmic)
- 13 Aug 2015 No recent reports on development identified - Phase-II for Bacterial infections (Prevention) in France and Spain (Ophthalmic)